![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CGA |
Gene summary for CGA |
![]() |
Gene information | Species | Human | Gene symbol | CGA | Gene ID | 1081 |
Gene name | glycoprotein hormones, alpha polypeptide | |
Gene Alias | CG-ALPHA | |
Cytomap | 6q14.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P01215 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1081 | CGA | GSM4909307 | Human | Breast | IDC | 1.11e-28 | 6.67e-01 | 0.1569 |
1081 | CGA | GSM4909308 | Human | Breast | IDC | 1.19e-15 | 3.73e-01 | 0.158 |
1081 | CGA | GSM4909319 | Human | Breast | IDC | 1.48e-02 | 2.39e-01 | 0.1563 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Breast | ![]() | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ | ||
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00022533 | Cervix | CC | activation of immune response | 72/2311 | 375/18723 | 8.26e-05 | 1.11e-03 | 72 |
GO:00903981 | Cervix | CC | cellular senescence | 25/2311 | 93/18723 | 1.11e-04 | 1.40e-03 | 25 |
GO:20010209 | Cervix | CC | regulation of response to DNA damage stimulus | 46/2311 | 219/18723 | 1.92e-04 | 2.23e-03 | 46 |
GO:00022183 | Cervix | CC | activation of innate immune response | 16/2311 | 52/18723 | 3.61e-04 | 3.75e-03 | 16 |
GO:00450882 | Cervix | CC | regulation of innate immune response | 44/2311 | 218/18723 | 6.40e-04 | 5.97e-03 | 44 |
GO:00026973 | Cervix | CC | regulation of immune effector process | 62/2311 | 339/18723 | 9.25e-04 | 7.84e-03 | 62 |
GO:00510528 | Cervix | CC | regulation of DNA metabolic process | 65/2311 | 359/18723 | 9.25e-04 | 7.84e-03 | 65 |
GO:00028331 | Cervix | CC | positive regulation of response to biotic stimulus | 35/2311 | 168/18723 | 1.23e-03 | 9.87e-03 | 35 |
GO:00324791 | Cervix | CC | regulation of type I interferon production | 21/2311 | 95/18723 | 5.32e-03 | 3.10e-02 | 21 |
GO:00326061 | Cervix | CC | type I interferon production | 21/2311 | 95/18723 | 5.32e-03 | 3.10e-02 | 21 |
GO:0045089 | Cervix | CC | positive regulation of innate immune response | 26/2311 | 131/18723 | 9.33e-03 | 4.66e-02 | 26 |
GO:00324815 | Cervix | CC | positive regulation of type I interferon production | 14/2311 | 58/18723 | 9.57e-03 | 4.73e-02 | 14 |
GO:00516072 | Cervix | CC | defense response to virus | 46/2311 | 265/18723 | 1.04e-02 | 4.97e-02 | 46 |
GO:01405462 | Cervix | CC | defense response to symbiont | 46/2311 | 265/18723 | 1.04e-02 | 4.97e-02 | 46 |
GO:0002230 | Cervix | CC | positive regulation of defense response to virus by host | 9/2311 | 31/18723 | 1.04e-02 | 4.97e-02 | 9 |
GO:014001414 | Esophagus | ESCC | mitotic nuclear division | 218/8552 | 287/18723 | 6.17e-26 | 1.78e-23 | 218 |
GO:000007011 | Esophagus | ESCC | mitotic sister chromatid segregation | 138/8552 | 168/18723 | 1.37e-22 | 2.63e-20 | 138 |
GO:00008194 | Esophagus | ESCC | sister chromatid segregation | 157/8552 | 202/18723 | 8.41e-21 | 1.33e-18 | 157 |
GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
GO:190285015 | Esophagus | ESCC | microtubule cytoskeleton organization involved in mitosis | 116/8552 | 147/18723 | 1.25e-16 | 9.91e-15 | 116 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CGA | SNV | Missense_Mutation | c.30N>G | p.Ile10Met | p.I10M | protein_coding | deleterious_low_confidence(0.02) | benign(0.295) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
CGA | SNV | Missense_Mutation | novel | c.232N>A | p.Ala78Thr | p.A78T | protein_coding | tolerated(0.53) | benign(0.121) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CGA | SNV | Missense_Mutation | c.433C>G | p.His145Asp | p.H145D | protein_coding | deleterious(0) | possibly_damaging(0.871) | TCGA-C5-A1BF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | ||
CGA | SNV | Missense_Mutation | rs145503313 | c.322N>A | p.Val108Ile | p.V108I | protein_coding | tolerated(1) | benign(0.001) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
CGA | SNV | Missense_Mutation | novel | c.373N>A | p.Val125Ile | p.V125I | protein_coding | tolerated(0.52) | benign(0.073) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CGA | SNV | Missense_Mutation | c.185N>A | p.Cys62Tyr | p.C62Y | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
CGA | SNV | Missense_Mutation | c.317N>C | p.Lys106Thr | p.K106T | protein_coding | deleterious(0) | possibly_damaging(0.836) | TCGA-AG-A026-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
CGA | SNV | Missense_Mutation | novel | c.4N>A | p.Asp2Asn | p.D2N | protein_coding | tolerated_low_confidence(0.07) | possibly_damaging(0.856) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CGA | SNV | Missense_Mutation | c.297N>T | p.Lys99Asn | p.K99N | protein_coding | deleterious(0.05) | possibly_damaging(0.51) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
CGA | SNV | Missense_Mutation | rs745838602 | c.407N>T | p.Ala136Val | p.A136V | protein_coding | deleterious(0.01) | benign(0.003) | TCGA-D1-A15W-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | VINBLASTINE | VINBLASTINE | 6181870 | |
1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | 4-{([(4'-CHLOROPHENYL)AMINO]CARBONYLAMINO)}BENZENESULFONAMIDE | CHEMBL1446150 | ||
1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | CIS-DIAMMINEDICHLOROPLATINUM | 6181870 | ||
1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | TUMOR NECROSIS FACTOR | 9764349,10788437 | ||
1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | IL-18 | 11712764 | ||
1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | 9-CIS-RETINOIC ACID | 8070357 | ||
1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | TESTOSTERONE | TESTOSTERONE | 1157041 | |
1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | CORTICOSTEROIDS | 3106008 |
Page: 1 |